aromasil has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N | 1 |
| Abramson, V; Awada, A; Biganzoli, L; Chan, S; Colleoni, M; Garcia-Estevez, L; Gucalp, A; Hart, L; Holmes, F; Kelly, CM; Krop, I; Markova, D; Morris, PG; O'Brien, T; Schwartzberg, L; Sica, L; Steinberg, J; Tarazi, J; Traina, T; Trudeau, M; Winer, E; Yardley, DA; Zamagni, C; Zhu, Z | 1 |
1 trial(s) available for aromasil and mdv 3100
| Article | Year |
|---|---|
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2020 |
1 other study(ies) available for aromasil and mdv 3100
| Article | Year |
|---|---|
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds | 2019 |